Reducing Recurrence of C. difficile Infection.
Where this comes from
- Record sourced from PubMed, PMID 28431238.
- Also identified by DOI 10.1016/j.cell.2017.03.039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clostridium difficile infection (CDI) is facilitated by alteration of the microbiome following antibiotic administration. Antimicrobial therapy directed against the pathogen can treat CDI. Unfortunately, ∼20% of successfully treated patients will suffer recurrence. Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B (TcdB), reducing recurrence presumably by limiting epithelial damage and facilitating microbiome recovery.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- Clostridioides difficile
- Enterocolitis, Pseudomembranous